Cargando…
Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
Breast cancer (BC) is the most common cancer in women and second only to lung cancer in terms of mortality. Among the three different BC subtypes, the oestrogen receptor positive represents nearly 70% of all cases and it is usually treated with anti-oestrogen drugs. However, the majority of hormone...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314865/ https://www.ncbi.nlm.nih.gov/pubmed/30622925 http://dx.doi.org/10.5306/wjco.v9.i8.172 |
_version_ | 1783384170823680000 |
---|---|
author | Sobhani, Navid Generali, Daniele Zanconati, Fabrizio Bortul, Marina Scaggiante, Bruna |
author_facet | Sobhani, Navid Generali, Daniele Zanconati, Fabrizio Bortul, Marina Scaggiante, Bruna |
author_sort | Sobhani, Navid |
collection | PubMed |
description | Breast cancer (BC) is the most common cancer in women and second only to lung cancer in terms of mortality. Among the three different BC subtypes, the oestrogen receptor positive represents nearly 70% of all cases and it is usually treated with anti-oestrogen drugs. However, the majority of hormone receptor positive metastatic BC patients develop resistance to anti-oestrogen treatments. The need for more down-stream therapies brought to the development of therapeutic strategies inhibiting the phosphatidylinositol 3-kinase-mammalian target of rapamycin (mTOR) pathway. Inhibitors of the mTOR have been tested in different clinical trials; everolimus has been Food and Drug Administration approved for the treatment of oestrogen receptor positive/human epidermal growth factor receptor 2 negative BC patients in combination with exemestane in patients who have progressed to anastrozole or letrozole after the encouraging results coming from BOLERO-2 trial. Similar results were obtained by the TAMRAD investigatory study testing tamoxifen in combination with everolimus in advanced BC. This editorial focuses on the results from BOLERO-2, BOLERO 4 and BOLERO-6, which tested the clinical importance of mTOR inhibition. We comment also on the role of phosphatidylinositol 3-kinase-mTOR inhibition as reported in the BELLE-2 and BELLE-3 trials and the future directions for the inhibition of this tumour metabolic axis. |
format | Online Article Text |
id | pubmed-6314865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-63148652019-01-08 Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer Sobhani, Navid Generali, Daniele Zanconati, Fabrizio Bortul, Marina Scaggiante, Bruna World J Clin Oncol Editorial Breast cancer (BC) is the most common cancer in women and second only to lung cancer in terms of mortality. Among the three different BC subtypes, the oestrogen receptor positive represents nearly 70% of all cases and it is usually treated with anti-oestrogen drugs. However, the majority of hormone receptor positive metastatic BC patients develop resistance to anti-oestrogen treatments. The need for more down-stream therapies brought to the development of therapeutic strategies inhibiting the phosphatidylinositol 3-kinase-mammalian target of rapamycin (mTOR) pathway. Inhibitors of the mTOR have been tested in different clinical trials; everolimus has been Food and Drug Administration approved for the treatment of oestrogen receptor positive/human epidermal growth factor receptor 2 negative BC patients in combination with exemestane in patients who have progressed to anastrozole or letrozole after the encouraging results coming from BOLERO-2 trial. Similar results were obtained by the TAMRAD investigatory study testing tamoxifen in combination with everolimus in advanced BC. This editorial focuses on the results from BOLERO-2, BOLERO 4 and BOLERO-6, which tested the clinical importance of mTOR inhibition. We comment also on the role of phosphatidylinositol 3-kinase-mTOR inhibition as reported in the BELLE-2 and BELLE-3 trials and the future directions for the inhibition of this tumour metabolic axis. Baishideng Publishing Group Inc 2018-12-20 2018-12-20 /pmc/articles/PMC6314865/ /pubmed/30622925 http://dx.doi.org/10.5306/wjco.v9.i8.172 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Editorial Sobhani, Navid Generali, Daniele Zanconati, Fabrizio Bortul, Marina Scaggiante, Bruna Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer |
title | Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer |
title_full | Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer |
title_fullStr | Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer |
title_full_unstemmed | Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer |
title_short | Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer |
title_sort | current status of pi3k-mtor inhibition in hormone-receptor positive, her2-negative breast cancer |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314865/ https://www.ncbi.nlm.nih.gov/pubmed/30622925 http://dx.doi.org/10.5306/wjco.v9.i8.172 |
work_keys_str_mv | AT sobhaninavid currentstatusofpi3kmtorinhibitioninhormonereceptorpositiveher2negativebreastcancer AT generalidaniele currentstatusofpi3kmtorinhibitioninhormonereceptorpositiveher2negativebreastcancer AT zanconatifabrizio currentstatusofpi3kmtorinhibitioninhormonereceptorpositiveher2negativebreastcancer AT bortulmarina currentstatusofpi3kmtorinhibitioninhormonereceptorpositiveher2negativebreastcancer AT scaggiantebruna currentstatusofpi3kmtorinhibitioninhormonereceptorpositiveher2negativebreastcancer |